Association between the subsequent benign prostate hyperplasia-related surgery risk and patients treated with Chinese herbal medicine: a population-based Taiwanese cohort study Authors: Ming-Yen Tsai, Chun-Ting Liu, Yu-Sin Shen, Hao-Lun Luo, Tai-Lin Chen, Ying-Hsiu Shih, Yu-Tung Hung, Tzu-Ju Hsu, Fuu-Jen Tsai, Yung-Hsiang Chen Published: 2026 ABSTRACT BackgroundThe association of Chinese herbal medicines (CHM) with the decreased risk of benign prostatic hyperplasia (BPH)-related surgery in patients with BPH is limited by the small sample size and short follow-up. We try to address this association in a large national sample using 21 years of data.MethodsA random sample composed of two million beneficiaries with newly diagnosed BPH between 2001 and 2016, followed until 2021 in Taiwan’s National Health Insurance Research Database was analyzed with a multivariate Cox proportional-hazards model. After 1:1 propensity score matching by baseline comorbidities, age, and the index year, a total of 11,172 patients were assigned to the CHM group (CHM + Western medicine) and 11,172 patients were assigned to the non-CHM group (Western medicine only). The occurrence of BPH-related surgery during the follow-up period was the primary outcome. The Kaplan-Meier method was used to calculate the cumulative incidence of BPH-related surgery in patients with BPH, both those who received CHM treatment and those who did not.ResultsDuring the study period, 875 CHM users and 870 CHM non-users underwent BPH-related surgery, resulting in surgery incidence rates of 6.89 and 7.26 per 1,000 person-years, respectively. Significantly fewer CHM users than CHM non-users received BPH-related surgery (adjusted HR = 0.89; 95% CI = 0.81, 0.98). A significantly lower risk was observed in those treated with CHM for more than 12 months. Dan Shen and Ji-Sheng-Shen-Qi-Wan were the most commonly prescribed single herb and CHM formula, respectively.ConclusionsOur study demonstrated that CHM may reduce the long-term risk of BPH-related surgery. Co-treatment with CHM reduced the risk of BPH-related surgery, especially in patients using CHM for over a year. Background Benign prostatic hyperplasia (BPH) is a chronic proliferative disease involving the non-malignant overgrowth of the epithelial and stromal cells from the transition zone and peri-urethral area in the prostate [1, 2]. BPH is characterized clinically by lower urinary tract symptoms (LUTS), which include urgency, hesitancy, frequency, weak and intermittent stream, straining to void, incomplete emptying, and nocturia [3, 4]. BPH profoundly impacts life quality and results in the majority of middle-aged to elderly men seeking medical treatment [5]. BPH affects approximately 90% of men aged ∼90 years, 80% of men aged ≥ 70 years, and 70% of men aged 60–69 years in the United States [6]. The goal of BPH treatment is to improve the irritative and obstructive symptoms. Current therapy options include lifestyle modifications, device and surgical approaches, and pharmaceutical interventions. Despite being regarded as the gold standard of care for BPH, transurethral resection of the prostate (TURP) still entails potential risks [7]. Medication to treat BPH remains a priority choice, including α-adrenergic blockers (AABs), phosphodiesterase 5 selective inhibitors (PDE5s), 5-α reductase inhibitors (5ARIs), anticholinergic drugs, and β-3 agonists. These drugs can be prescribed alone or combined to make use of their specific actions [8]. For example, 5ARIs suppress androgen action by preventing testosterone from converting to dihydrotestosterone [9]. Long-term treatment with 5-ARIs can effectively reduce prostate volume by 25% [10], BPH-related surgery, and risk of acute urine retention [11]. AABs have been found to improve LUTS related to BPH and provide quicker symptom relief compared to 5ARIs [12]; however, AABs have no significant effect on BPH progression [11]. Two recent studies demonstrated that the risk of overall BPH progression was reduced more by combination therapy of AAB and 5ARI than by either monotherapy [13]. While these drugs have been shown to be useful in reducing the symptoms of BPH, numerous studies have demonstrated undesirable and serious adverse events (AEs) [14]. The most common AEs in recipients are decreased libido, sexual dysfunction, skin rash, and gynecomastia with 5ARIs, as well as asthenia, dizziness, and rhinitis with AABs [9, 14]. In both studies of Combination of Avodart and Tamsulosin (CombAT) and Medical Therapy of Prostatic Symptoms (MTOPS), Western medicine (WM)-related AEs were more frequent during combination therapy than during either AAB or 5ARI alone [15]. As these synthetic agents pose several complications, effective remedies for BPH are being considered. Complementary and alternative medicine for the symptomatic improvement of BPH has been sought and assessed for years [16]. Chinese herbal medicine (CHM) is one commonly used adjuvant option to manage BPH [17]. It has been reported that Cortex Cinnamomi, Radix Astragali, Ji-Shen-Shen-Qi-Wan, and Ba-Wei-Di-Huang-Wan may have the potential to improve BPH [18]. A prior systematic review and network meta-analysis suggests that combining CHM with WM may provide greater therapeutic benefits for BPH than WM alone [17]. Although CHM has been widely used and reported to alleviate BPH-related symptoms [17, 18], its effect on reducing the risk of BPH-related surgeries remains uncertain. TCM is a medical option used by more than 60% of all subjects in Taiwan, and since 1995, it has been covered by the National Health Insurance (NHI) system [19]. The AEs of conventional drugs can be bothersome, and patients are hesitant to consent to surgery, but CHM might provide a solution to these problems. To investigate the feasibility of CHM as a treatment choice, and to bolster the real-world evidence in this field, we analyzed a randomly sampled cohort of two million individuals from 2000 to 2021 using the National Health Insurance Research Database (NHIRD). Materials and methods Data source This cohort study was conducted using the 2 million–person subset of the NHIRD. The database was launched in 1995 and covers more than 99% of the entire Taiwanese population. The NHIRD contains patients’ demographic and medical information, including disease diagnoses, prescription details, operations, and investigations. All datasets are de-identified. To identify the disease, we utilized the International Classification of Diseases, Clinical Modification (ICD-9-CM), and the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Study population The study cohort was patients with newly diagnosed BPH (ICD-9-CM:600, ICD-10-CM: N40) from 2001 to 2016, and the follow-up to 2021. We divided patients into two groups. Those who were treated with both WM and CHM were defined as CHM users (case group), and those who were treated with only WM were defined as CHM non-users (control group). For CHM users, the index date was defined as the date of their first CHM prescription after the BPH diagnosis. In contrast, for CHM non-users, the index date was randomly chosen after the BPH diagnosis. We matched CHM users and non-users with a 1:1 ratio by age (every 5 years), WM, baseline comorbidities, and index year. The exclusion criteria for the participants included the index date before 2001 and after 2016, adult male less than 40 years of age, history of prostate surgery or death before the index date, follow-up of less than 5 years, history of colorectal cancer or prostate cancer, subjects with acupuncture treatment, the duration from BPH diagnosis to the index date exceeded 3 years, the cumulative CHM treatment duration was less than 3 months, and missing data in patient registries. Figure 1 illustrates a flowchart depicting the process of selecting study participants. Fig. 1Flow chart of the recruitment of study subjects Flow chart of the recruitment of study subjects Main outcome and relevant variables The main outcome of our study was the occurrence of BPH-related surgery, including (CODE 79406B (TURP 5–15 gms), 79411B (TURP 15–50 gms), 79412B (TURP > 50 gms), 79413B (Biopolar TURP/TUVP 5–15 gms), 79414B (Biopolar TURP/TUVP 15–50 gms), 79415B (Bipolar TURP/TUVP > 50 gms), N20001 (Bipolar TURP/TUVP), N20002 (GreenLight PVP), N20003 (Thulium Laser Vaporesection of the Prostate), N20004 (HoLEP Vaporesection of the Prostate), and N20005 [Diode laser (980 nm) enucleation of the Prostate)]. Both cohorts were followed until the occurrence of prostate surgery, death, or December 31, 2021. Comorbidity was defined as the co-occurrence of at least 2 outpatient visits or 1 inpatient hospitalization. Clinical relevant comorbidities included CVD (ICD-9-CM codes 410–414; ICD-10-CM codes I20–I25), cerebrovascular accident (CVA) (ICD-9-CM codes 571.0–571.3; ICD-10-CM codes K70.0–K70.9), hypertension (ICD-9-CM codes 401–405; ICD-10-CM code I10), erectile dysfunction (ICD-9-CM code 607.84; ICD-10-CM code N52), and diabetes mellitus (DM) (ICD-9-CM code 250; ICD-10-CM codes E08–E13). Treatment with WM (including AARs, 5ARIs and combined therapy) and the Medication Possession Ratio (MPR) were also examined. Statistical analyses SAS version 9.4 (SAS Institute Inc., Cary, NC) was used for the statistical analyses. Categorical variables are presented as counts and percentages, while continuous variables are presented as means and standard deviations. The chi-squared test was used to analyze the categorical variables, and the Student’s t test was used to analyze the continuous variables. In the univariate Cox proportional hazards model, we calculated the hazard ratios (HR) and 95% confidence intervals (95% CI). Age, monthly income, urbanization level, and comorbidities were considered in the multivariable Cox proportional hazards regression model. The Kaplan–Meier method was used to plot the cumulative incidence and survival curves. P-values less than 0.05 were considered statistically significant. Results Table 1 shows the study cohort baseline characteristics. After propensity score matching, a total of 22,344 BPH patients were enrolled in the study, with 11,172 patients in each group. BPH patients who use CHM were sociodemographically different from non-users, particularly in terms of income and urbanization level, with a tendency towards higher income and greater urbanization. CHM users also showed a significantly higher tendency to use 5ARIs or combined therapy for BPH than non-users. The baseline health status, as measured by major comorbidities, was not significantly different. The mean follow-up times for CHM non-users and CHM users were 10.72 years and 11.36 years, respectively. The MPR of WM was significantly lower in CHM users compared to CHM non-users. Table 1Demographic and clinical characteristics of patients with BPH with and without CHMCHM non-usersCHM users(N = 11172)(N = 11172)Variablesn%n%p-valueAge0.029 40–55264123.64266223.83 56–70542148.52557249.87 > 70311027.84293826.30 mean, (SD) †63.5710.0563.3710.000.140Monthly income (NTD)< 0.001 < 18,000314628.16276724.77 18,000–34,999573151.30604454.10 > 34,999229520.54236121.13Urban0.005 Low10559.449948.90 Median378533.88360632.28 High633256.68657258.83Comorbidities Cardiovascular disease278024.88279024.970.877 Cerebrovascular accident173415.52172715.460.897 Hypertension630156.40620755.560.205 Erectile dysfunction3332.983312.960.937 Diabetes mellitus269124.09266423.850.672Western medications used during the study period α1-adrenergic blockers11,15299.8211,16199.900.106 5α reductase inhibitors244621.89274924.61< 0.001 Combined therapy2552.283433.07< 0.001Mean follow-up years, (SD) †10.724.0711.364.12< 0.001Mean MPR, % (SD) †22.5420.4320.7918.51< 0.001MPR Medication Possession Ratio†: Student’s t-test; Chi-square test Table 1Demographic and clinical characteristics of patients with BPH with and without CHMCHM non-usersCHM users(N = 11172)(N = 11172)Variablesn%n%p-valueAge0.029 40–55264123.64266223.83 56–70542148.52557249.87 > 70311027.84293826.30 mean, (SD) †63.5710.0563.3710.000.140Monthly income (NTD)< 0.001 < 18,000314628.16276724.77 18,000–34,999573151.30604454.10 > 34,999229520.54236121.13Urban0.005 Low10559.449948.90 Median378533.88360632.28 High633256.68657258.83Comorbidities Cardiovascular disease278024.88279024.970.877 Cerebrovascular accident173415.52172715.460.897 Hypertension630156.40620755.560.205 Erectile dysfunction3332.983312.960.937 Diabetes mellitus269124.09266423.850.672Western medications used during the study period α1-adrenergic blockers11,15299.8211,16199.900.106 5α reductase inhibitors244621.89274924.61< 0.001 Combined therapy2552.283433.07< 0.001Mean follow-up years, (SD) †10.724.0711.364.12< 0.001Mean MPR, % (SD) †22.5420.4320.7918.51< 0.001MPR Medication Possession Ratio†: Student’s t-test; Chi-square test Demographic and clinical characteristics of patients with BPH with and without CHM MPR Medication Possession Ratio †: Student’s t-test; Chi-square test Table 2 presents the risk of BPH-related surgery by exposure, demographics, comorbidities, and medications. CHM users had a significantly lower risk of BPH-related surgery than CHM non-users (aHR, 0.89; 95% CI, 0.81, 0.98) after controlling for sex, age, monthly income, urbanization level, and comorbidities. Patients aged 56–70 years (aHR, 2.09; 95% CI, 1.82, 2.40) and those aged more than 70 years (aHR, 1.77; 95% CI, 1.50, 2.08) had significantly higher risk of BPH-related surgery than did those aged 40–55 years. Patients with BPH with monthly incomes of NTD 18,000–34,999 (aHR, 1.35; 95% CI, 1.20, 1.52) and more than 34,999 (aHR, 1.23; 95% CI, 1.06, 1.42) had a significantly higher risk of BPH-related surgery than did those earning less than NTD 18,000 per month. Patients with CVD (aHR, 0.84; 95% CI, 0.74, 0.95) and CVA (aHR, 0.83; 95% CI, 0.72, 0.97) had lower risk of BPH-related surgery than did their counterparts without these comorbidities. Table 2IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery in patients with BPHBPH-related surgeryVariablesnPYIRcHR(95% CI)p-valueaHR†(95% CI)p-valueCHM non-users870119774.327.261.00(reference)-1.00(reference)-CHM users875126924.596.890.90(0.82, 0.99)*0.0290.89(0.81, 0.98)*0.015Age 40–5525359154.184.281.00(reference)-1.00(reference)- 56–701059122383.308.652.02(1.76, 2.32)***<0.0012.09(1.82, 2.40)***<0.001 > 7043365161.426.651.60(1.37, 1.87)***<0.0011.77(1.50, 2.08)***<0.001Monthly income (NTD) < 18,00039665309.806.061.00(reference)-1.00(reference)- 18,000–34,999989128972.507.671.28(1.14, 1.44)***<0.0011.35(1.20, 1.52)***<0.001 > 34,99936052416.616.871.12(0.97, 1.29)0.1281.23(1.06, 1.42)**0.006Urban Low16922398.177.551.00(reference)-1.00(reference)- Median60681037.407.480.99(0.83, 1.17)0.8911.03(0.87, 1.22)0.756 High970143263.336.770.88(0.75, 1.04)0.1400.94(0.79, 1.10)0.430Comorbidities Cardiovascular disease36459999.356.070.85(0.75, 0.95)**0.0050.84(0.74, 0.95)**0.005 Cerebrovascular accident20835954.555.790.85(0.74, 0.98)*0.0290.83(0.72, 0.97)*0.016 Hypertension910135394.916.720.93(0.85, 1.03)0.1560.94(0.85, 1.04)0.250 Erectile dysfunction406986.575.730.84(0.62, 1.15)0.2840.90(0.65, 1.23)0.491 Diabetes mellitus34756241.036.170.90(0.80, 1.01)0.0660.92(0.82, 1.04)0.166PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p < 0.05; **p < 0.01, ***p < 0.001 Table 2IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery in patients with BPHBPH-related surgeryVariablesnPYIRcHR(95% CI)p-valueaHR†(95% CI)p-valueCHM non-users870119774.327.261.00(reference)-1.00(reference)-CHM users875126924.596.890.90(0.82, 0.99)*0.0290.89(0.81, 0.98)*0.015Age 40–5525359154.184.281.00(reference)-1.00(reference)- 56–701059122383.308.652.02(1.76, 2.32)***<0.0012.09(1.82, 2.40)***<0.001 > 7043365161.426.651.60(1.37, 1.87)***<0.0011.77(1.50, 2.08)***<0.001Monthly income (NTD) < 18,00039665309.806.061.00(reference)-1.00(reference)- 18,000–34,999989128972.507.671.28(1.14, 1.44)***<0.0011.35(1.20, 1.52)***<0.001 > 34,99936052416.616.871.12(0.97, 1.29)0.1281.23(1.06, 1.42)**0.006Urban Low16922398.177.551.00(reference)-1.00(reference)- Median60681037.407.480.99(0.83, 1.17)0.8911.03(0.87, 1.22)0.756 High970143263.336.770.88(0.75, 1.04)0.1400.94(0.79, 1.10)0.430Comorbidities Cardiovascular disease36459999.356.070.85(0.75, 0.95)**0.0050.84(0.74, 0.95)**0.005 Cerebrovascular accident20835954.555.790.85(0.74, 0.98)*0.0290.83(0.72, 0.97)*0.016 Hypertension910135394.916.720.93(0.85, 1.03)0.1560.94(0.85, 1.04)0.250 Erectile dysfunction406986.575.730.84(0.62, 1.15)0.2840.90(0.65, 1.23)0.491 Diabetes mellitus34756241.036.170.90(0.80, 1.01)0.0660.92(0.82, 1.04)0.166PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p < 0.05; **p < 0.01, ***p < 0.001 IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery in patients with BPH PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio †: adjusted by sex, age, monthly income, urban, and comorbidities *: p < 0.05; **p < 0.01, ***p < 0.001 Using the Kaplan-Meier method, Fig. 2 displays the cumulative incidence of BPH-related surgery in patients with and without CHM treatment. It reveals that CHM users had a significantly lower cumulative incidence of BPH-related surgery compared to CHM non-users. Table 3 presents the 95% confidence intervals and hazard ratios (HRs) for the risk of undergoing prostate surgery by stratification of CHM treatment duration, adjusted for age, monthly income, urbanization level, and comorbidities. Patients with BPH who used CHM for 12–36 months (aHR, 0.85; 95% CI, 0.74, 0.98) and for more than 36 months (aHR, 0.65; 95% CI, 0.52, 0.81) had a significantly lower risk of BPH-related surgery compared with CHM non-users. Fig. 2Kaplan–Meier analysis showed the cumulative incidence of BPH-related surgery in BPH patients with CHM and non-CHM treatment Kaplan–Meier analysis showed the cumulative incidence of BPH-related surgery in BPH patients with CHM and non-CHM treatment Table 3IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery stratified by the duration of CHM useVariablesBPH-related surgery n PYIRcHR(95% CI)p-valueaHR†(95% CI)p-valueCHM non-users870119774.327.261.00(reference)-1.00(reference)-CHM users 3–12 months53572065.177.420.99(0.88, 1.10)0.7890.97(0.87, 1.08)0.578 12–36 months25739214.956.550.86(0.74, 0.98)*0.0280.85(0.74, 0.98)*0.021 > 36 months8315644.475.310.65(0.52, 0.81)***< 0.0010.65(0.52, 0.81)***< 0.001PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p < 0.05; **p < 0.01, ***p < 0.001 Table 3IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery stratified by the duration of CHM useVariablesBPH-related surgery n PYIRcHR(95% CI)p-valueaHR†(95% CI)p-valueCHM non-users870119774.327.261.00(reference)-1.00(reference)-CHM users 3–12 months53572065.177.420.99(0.88, 1.10)0.7890.97(0.87, 1.08)0.578 12–36 months25739214.956.550.86(0.74, 0.98)*0.0280.85(0.74, 0.98)*0.021 > 36 months8315644.475.310.65(0.52, 0.81)***< 0.0010.65(0.52, 0.81)***< 0.001PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p < 0.05; **p < 0.01, ***p < 0.001 IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery stratified by the duration of CHM use PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio †: adjusted by sex, age, monthly income, urban, and comorbidities *: p < 0.05; **p < 0.01, ***p < 0.001 Table 4 compares the risk of BPH-related surgery between both groups, stratified by demographics and comorbidities. CHM users were at lower risk for receiving BPH-related surgery than CHM non-users, particularly those with an age of 56 to 70 years (aHR, 0.86; 95% CI, 0.76, 0.97), a monthly income of more than 34,999 (aHR, 0.80; 95% CI, 0.65, 0.99), and low (aHR, 0.71; 95% CI, 0.53, 0.97) or medium urbanized environment (aHR, 0.77; 95% CI, 0.66, 0.91). In addition, CHM users without CVD, CVA, hypertension, erectile dysfunction, or DM had lower risk of BPH-related surgery than did CHM non-users. Table 4IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery with and without CHM treatmentVariableCHM non-usersCHM users n PYIR n PYIRcHRcCIP-valueaHR†aCIP-valueAge 40–5512029011.484.1413330142.704.411.03(0.81, 1.32)0.8071.03(0.80, 1.32)0.829 56–7053158542.759.0752863840.558.270.86(0.77, 0.98)*0.0180.86(0.76, 0.97)*0.016 > 7021932220.086.8021432941.346.500.90(0.75, 1.09)0.2720.89(0.74, 1.08)0.232Monthly income (NTD) < 18,00020433743.416.0519231566.386.080.95(0.78, 1.16)0.6380.96(0.79, 1.17)0.676 18,000–34,99947760770.337.8551268202.177.510.90(0.80, 1.02)0.1070.90(0.79, 1.02)0.086 > 34,99918925260.577.4817127156.046.300.81(0.66, 0.99)*0.0440.80(0.65, 0.99)*0.039Urban Low9411036.318.527511361.866.600.73(0.54, 0.98)*0.0390.71(0.53, 0.97)*0.030 Median32539797.578.1728141239.836.810.78(0.66, 0.91)**0.0020.77(0.66, 0.91)**0.002 High45168940.446.5451974322.906.981.03(0.91, 1.17)0.6541.02(0.90, 1.16)0.781Comorbidities Cardiovascular disease No69390753.737.6468895945.827.170.89(0.80, 0.99)*0.0320.88(0.79, 0.98)*0.019 Yes17729020.596.1018730978.776.040.94(0.76, 1.15)0.5410.93(0.75, 1.14)0.469Cerebrovascular accident No775102608.147.55762108136.227.050.89(0.81, 0.98)*0.0230.88(0.79, 0.97)*0.011 Yes9517166.185.5311318788.376.011.01(0.77, 1.33)0.9531.00(0.76, 1.32)0.988Hypertension No44153527.178.2439457776.826.820.79(0.69, 0.90)***< 0.0010.77(0.67, 0.88)***< 0.001 Yes42966247.146.4848169147.776.961.02(0.90, 1.16)0.7571.02(0.89, 1.16)0.804Erectile dysfunction No854116218.327.35851123494.026.890.89(0.81, 0.98)*0.0140.88(0.80, 0.97)**0.008 Yes163555.994.50243430.577.001.63(0.86, 3.07)0.1321.65(0.87, 3.12)0.125Diabetes mellitus No71692411.507.7568298046.376.960.85(0.77, 0.95)**0.0030.84(0.76, 0.93)**0.001 Yes15427362.825.6319328878.226.681.11(0.90, 1.38)0.3191.12(0.90, 1.38)0.302PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p-value < 0.05; **p < 0.01, ***p < 0.001 Table 4IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery with and without CHM treatmentVariableCHM non-usersCHM users n PYIR n PYIRcHRcCIP-valueaHR†aCIP-valueAge 40–5512029011.484.1413330142.704.411.03(0.81, 1.32)0.8071.03(0.80, 1.32)0.829 56–7053158542.759.0752863840.558.270.86(0.77, 0.98)*0.0180.86(0.76, 0.97)*0.016 > 7021932220.086.8021432941.346.500.90(0.75, 1.09)0.2720.89(0.74, 1.08)0.232Monthly income (NTD) < 18,00020433743.416.0519231566.386.080.95(0.78, 1.16)0.6380.96(0.79, 1.17)0.676 18,000–34,99947760770.337.8551268202.177.510.90(0.80, 1.02)0.1070.90(0.79, 1.02)0.086 > 34,99918925260.577.4817127156.046.300.81(0.66, 0.99)*0.0440.80(0.65, 0.99)*0.039Urban Low9411036.318.527511361.866.600.73(0.54, 0.98)*0.0390.71(0.53, 0.97)*0.030 Median32539797.578.1728141239.836.810.78(0.66, 0.91)**0.0020.77(0.66, 0.91)**0.002 High45168940.446.5451974322.906.981.03(0.91, 1.17)0.6541.02(0.90, 1.16)0.781Comorbidities Cardiovascular disease No69390753.737.6468895945.827.170.89(0.80, 0.99)*0.0320.88(0.79, 0.98)*0.019 Yes17729020.596.1018730978.776.040.94(0.76, 1.15)0.5410.93(0.75, 1.14)0.469Cerebrovascular accident No775102608.147.55762108136.227.050.89(0.81, 0.98)*0.0230.88(0.79, 0.97)*0.011 Yes9517166.185.5311318788.376.011.01(0.77, 1.33)0.9531.00(0.76, 1.32)0.988Hypertension No44153527.178.2439457776.826.820.79(0.69, 0.90)***< 0.0010.77(0.67, 0.88)***< 0.001 Yes42966247.146.4848169147.776.961.02(0.90, 1.16)0.7571.02(0.89, 1.16)0.804Erectile dysfunction No854116218.327.35851123494.026.890.89(0.81, 0.98)*0.0140.88(0.80, 0.97)**0.008 Yes163555.994.50243430.577.001.63(0.86, 3.07)0.1321.65(0.87, 3.12)0.125Diabetes mellitus No71692411.507.7568298046.376.960.85(0.77, 0.95)**0.0030.84(0.76, 0.93)**0.001 Yes15427362.825.6319328878.226.681.11(0.90, 1.38)0.3191.12(0.90, 1.38)0.302PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p-value < 0.05; **p < 0.01, ***p < 0.001 IRs and crude and adjusted HRs with 95% CIs of BPH-related surgery with and without CHM treatment PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio †: adjusted by sex, age, monthly income, urban, and comorbidities *: p-value < 0.05; **p < 0.01, ***p < 0.001 Table 5 lists the top ten single herbs and CHM formulas for the treatment of BPH in the study cohort. Dan Shen and Ji-Sheng-Shen-Qi-Wan (JSSQW) were the most common single herb and CHM formula, respectively. Table 5Top ten most common CHM herbs and formulas for patients with BPHFrequencyNumber of person-daysAverage daily dose (g)Average duration for prescription (days)Single Herbs (Latin) Dan Shen (Salvia miltiorrhiza)12914211620509.01.9 Yan Hu Suo (Corydalis yanhusuo)1116477712156.92.0 Da Huang (Rheum officinale)1115899026968.11.3 Bei Mu (Fritillariae Thunbergii)911086780617.42.2 Huang Qi (Astragalus membranaceus)886817730188.72.0 Jie Geng (Platycodon grandiflorus)874555984186.81.6 Huang Qin (Scutellaria baicalensis)849666597037.82.2 Du Zhong (Eucommia ulmoides)829316849098.31.9 Hou Po (Houpoea officinalis)754556036828.01.9 Ge Gen (Pueraria montana var. lobata)726035349437.42.3CHM Formula (in Chinese) Ji-Sheng-Shen-Qi-Wan16752814095668.46.9 Shu-Jing-Huo-Xue-Tang1138127596076.78.7 Liu-Wei-Di-Huang-Wan822226589268.07.3 Du-Huo-Ji-Sheng-Tang808266038637.58.3 Shao-Yao-Gan-Cao-Tang775275126036.66.9 Ping-Wei-San753595231746.95.6 Xue-Fu-Zhu-Yu-Tang753576044028.06.2 Ma-Zi-Ren-Wan749166304808.46.2 Jia-Wei-Xiao-Yao-San748486379098.57.2 Ban-Xia-Xie-Xin-Tang743945646437.67.4 Table 5Top ten most common CHM herbs and formulas for patients with BPHFrequencyNumber of person-daysAverage daily dose (g)Average duration for prescription (days)Single Herbs (Latin) Dan Shen (Salvia miltiorrhiza)12914211620509.01.9 Yan Hu Suo (Corydalis yanhusuo)1116477712156.92.0 Da Huang (Rheum officinale)1115899026968.11.3 Bei Mu (Fritillariae Thunbergii)911086780617.42.2 Huang Qi (Astragalus membranaceus)886817730188.72.0 Jie Geng (Platycodon grandiflorus)874555984186.81.6 Huang Qin (Scutellaria baicalensis)849666597037.82.2 Du Zhong (Eucommia ulmoides)829316849098.31.9 Hou Po (Houpoea officinalis)754556036828.01.9 Ge Gen (Pueraria montana var. lobata)726035349437.42.3CHM Formula (in Chinese) Ji-Sheng-Shen-Qi-Wan16752814095668.46.9 Shu-Jing-Huo-Xue-Tang1138127596076.78.7 Liu-Wei-Di-Huang-Wan822226589268.07.3 Du-Huo-Ji-Sheng-Tang808266038637.58.3 Shao-Yao-Gan-Cao-Tang775275126036.66.9 Ping-Wei-San753595231746.95.6 Xue-Fu-Zhu-Yu-Tang753576044028.06.2 Ma-Zi-Ren-Wan749166304808.46.2 Jia-Wei-Xiao-Yao-San748486379098.57.2 Ban-Xia-Xie-Xin-Tang743945646437.67.4 Top ten most common CHM herbs and formulas for patients with BPH Table 6 shows that CHM users had a significantly lower risk of BPH-related surgery compared with CHM non-users among patients with the MPR < 8%, but no statistically significant difference was observed in patients with higher MPR levels. Table 6Risk of BPH-related surgery stratified by Western medication Possession Ratio (MPR) with and without CHM treatmentVariableCHM non-usersCHM users n PYIR n PYIRcHRcCIP-valueaHR†aCIP-valueMPR < 8%19443998.274.4115043880.543.420.79(0.63, 0.97)*0.0260.78(0.63, 0.97)*0.023 8–27%28544308.966.4332549876.246.521.00(0.85, 1.17)0.9940.99(0.85, 1.16)0.912 > 27%39145877.578.5240040960.269.771.12(0.98, 1.29)0.1041.12(0.98, 1.29)0.101PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p-value < 0.05; **p < 0.01, ***p < 0.001 Table 6Risk of BPH-related surgery stratified by Western medication Possession Ratio (MPR) with and without CHM treatmentVariableCHM non-usersCHM users n PYIR n PYIRcHRcCIP-valueaHR†aCIP-valueMPR < 8%19443998.274.4115043880.543.420.79(0.63, 0.97)*0.0260.78(0.63, 0.97)*0.023 8–27%28544308.966.4332549876.246.521.00(0.85, 1.17)0.9940.99(0.85, 1.16)0.912 > 27%39145877.578.5240040960.269.771.12(0.98, 1.29)0.1041.12(0.98, 1.29)0.101PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio†: adjusted by sex, age, monthly income, urban, and comorbidities*: p-value < 0.05; **p < 0.01, ***p < 0.001 Risk of BPH-related surgery stratified by Western medication Possession Ratio (MPR) with and without CHM treatment PY person-years, IR incidence rate per 1,000 person-years, cHR crude hazard ratio, aHR adjusted hazard ratio †: adjusted by sex, age, monthly income, urban, and comorbidities *: p-value < 0.05; **p < 0.01, ***p < 0.001 Discussion Our study is the first to investigate the relationship between CHM use and the risk of BPH-related surgery. This study carefully balanced age, monthly income, urbanization level, and comorbidities between CHM users and non-users. Our findings revealed an 11% lower risk of BPH-related surgery in CHM users compared to non-users. Notably, BPH patients aged 56–70 and over 70 exhibited 2.09 and 1.77 times higher surgery risk, respectively, than those aged 40–55. Interestingly, CHM users aged 56–70 showed significantly reduced surgery risk compared to non-users. Besides, patients with BPH with monthly incomes of NTD 18,000–34,999 and more than 34,999 had a significantly higher surgery risk than those earning less than NTD 18,000 per month. However, CHM users with a monthly income exceeding NTD 34,999 and those residing in low and moderate urbanized areas faced lower risks of BPH-related surgery. Among comorbidities, the absence of CVD, CVA, hypertension, erectile dysfunction, or DM correlated with reduced surgery risk. Notably, CHM usage for 12–36 months and over 36 months led to substantial decreases in BPH-related surgery risk compared to non-users. JSSQW and Dan Shen emerged as the most prescribed CHM formula and single herb, respectively. BPH, an age-linked condition, can obstruct the prostatic urethra [5], with LUTS being its main hallmark. Ongoing prostate growth raises LUTS progression risk [20]. BPH-related surgery becomes necessary if medications fail, LUTS become unbearable, or complications like recurrent bladder stones, hematuria, urinary retention, urinary tract infections, and renal issues arise [21]. Progressing LUTS often prompts surgical considerations. Our study found that BPH patients aged 56–70 and over 70 were more prone to BPH-related surgery than those aged 40–55, aligning with aging’s increased BPH risk. Remarkably, CHM users aged 56–70 displayed significantly lower surgery risk than non-users. Taiwan’s CHM use rate is higher among those over 65, potentially due to their chronic conditions [22], which CHM can manage while alleviating BPH-related LUTS and potentially delaying surgery [23]. Due to the gradual progression of LUTS, only 10% of middle-aged men with BPH undergo surgery within a 5-year period [24]. This highlights the importance of CHM’s long-term effects in the treatment of BPH. Ou’s study demonstrated the efficacy of CHM in improving BPH-related complications over a period exceeding 60 days [23]. Our findings showed that BPH patients using CHM for 12–36 months and those using it for over 36 months had reduced surgical risks, at 0.85 and 0.65 times, respectively, compared to non-users. Ou’s research focused on acute BPH complications, such as urinary tract infections and urine retention, which generally respond well to conservative treatments. In contrast, our study focused on BPH-related surgeries, which are typically recommended when conservative approaches are ineffective or complications occur. Therefore, we suggest that a minimum of one year of CHM usage may be needed to meaningfully reduce the risk of BPH-related surgery. Additionally, while Ou’s study considered only monopolar TURP, our study included a wider range of surgical interventions, including monopolar TURP, bipolar TURP/TUVP, and laser prostatectomy. Although our findings align with Ou’s in showing a significantly reduced risk of BPH-related surgery among CHM users, our study further expands these observations to encompass multiple surgical modalities. A 4-year study revealed that combining dutasteride and tamsulosin for BPH patients with moderate-to-severe LUTS reduced the risk of acute urine retention or BPH-related surgery by 66%, compared to tamsulosin alone. However, the combined therapy group experienced higher rates of adverse events, primarily ejaculatory disorders [25]. We found that adherence to prescribed WM was significantly lower among CHM users than among non-users. In line with TCM theory, which associates erectile dysfunction with kidney deficiency [26], some common CHMs in our study aimed to strengthen kidney yin or yang. These include Du Zhong, JSSQW, Du-Huo-Ji-Sheng-Tang, and Liu-Wei-Di-Huang-Wan, which may potentially alleviate erectile issues. CHM not only proves safe in monotherapy and CAM trials but can also mitigate WM side effects [27]. For instance, Panax ginseng extract was shown to treat BPH and reduce finasteride-related side effects in BPH models [28]. The slower action of 5ARIs and their troublesome adverse effects likely contribute to the prevalent CHM use observed in our study. Prior research [29] suggests that poor adherence to 5ARIs treatment in BPH patients raises the risk of BPH-related surgery. However, our study results demonstrate that the risk of BPH-related surgery can be reduced by 22% in patients with low WM adherence (MPR < 8%) who receive CHM treatment. This finding highlights the clinical utility of CHM as an effective alternative for preventing surgery in BPH patients who are unable to tolerate or maintain adherence to standard WM treatments. In our study, Dan Shen and JSSQW were the most frequently prescribed CHMs for BPH. Dan Shen is traditionally used for pain relief, improving blood circulation, and enhancing anti-coagulant effects in cardiovascular health [30]. Its anti-oxidative and anti-inflammatory properties also counteract BPH’s inflammatory and oxidative factors [31]. Tanshinones from Dan Shen have shown potential in inhibiting prostate tumor growth by targeting androgen receptor signaling [32]. JSSQW is a common choice for treating LUTS [33], effectively addressing overactive bladder symptoms [34]. Its mechanisms involve blocking spinal kappa-opioid receptors to modulate bladder sensation and maintain balance in the autonomic nervous system to control bladder activity. In contrast to AARs and 5ARIs, which can cause erectile dysfunction, JSSQW has been reported to alleviate erectile dysfunction by reducing PDE5 expression [35]. Our study provided real-world evidence of CHM’s ability to reduce surgical risk in patients with BPH. However, our research has limitations. Some globally used natural remedies for BPH, such as pumpkin (Cucurbita pepo L.) seed oil, are not covered by Taiwan’s NHI system, potentially leading to an underestimated surgery risk reduction [36]. Emerging minimally invasive surgical therapies, such as PAE, Urolift, Rezum, TIND/iTIND, and TUMT, are gaining popularity for BPH [37]. However, only PAE is currently available in Taiwan and not covered by NHI. This limits their usage. Additionally, our data couldn’t assess lifelong surgery risk or the combined effects of CHM and WM, warranting further investigation [38]. Finally, the study cannot estimate defined daily doses or medication possession ratios, as the NHIRD data are based on drug item codes. The NHI program only covers daily drug costs without regulating daily dosage limits or the number of drugs prescribed by TCM doctors. Nonetheless, we can still rely on real-world evidence to support prescriptions targeting core pathogenesis and streamline TCM prescription components for effective treatment. Conclusion Our study demonstrated that co-treatment with CHM reduced the risk of BPH-related surgery, especially in patients using CHM for over a year. This led to more precise results. Given the heightened prostate cancer risk in BPH patients, particularly among Asians [39], certain CHMs like Dan Shen show promise against prostate cancer [32]. Further research is needed to explore the link between CHM and prostate cancer risk in BPH patients, and to develop new compounds for BPH treatment.